Month: February 2025

Flow Traders 4Q and FY 2024 Results Amsterdam, the Netherlands – Flow Traders Ltd. (Euronext: FLOW) announces its unaudited 4Q and FY 2024 results. Flow Traders posts record fourth quarter results and the second-best fiscal year results in its 20-year history with €159.0m and €479.3m in Total Income, respectively. The company also ends 2024 with record levels of Trading Capital and Shareholders’ Equity at €775m and €766m, respectively. Financial Highlights 4Q 2024Flow Traders recorded Net Trading Income of €153.8m and Total Income of €159.0m in 4Q24, increases of 112% and 114% when compared to the €72.7m and €74.3m in 4Q23, respectively. Flow Traders’ ETP Value Traded increased by 13% in 4Q24 to €424m from €376m in 4Q23. Fixed Operating Expenses were €45.3m in the quarter, an increase of 12% when compared to the €40.4m in 4Q23,...

Oslo, Norway, 13th of February 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2024. Revenue in the fourth quarter ended at MNOK 114 compared to MNOK 111 in Q4 2023. Strong operational performance resulted in more volumes available for sale in the quarter, which increased the sales volume with 11%. 2024 full year revenue ended at MNOK 430 compared to MNOK 438 last year. Sales volume increased by 4% in 2024, even with an unplanned stop on line 2 in Q1. Fourth quarter EBITDA ended at MNOK 28 compared to MNOK 25 in Q4 2023. EBITDA positively affected by increased sales volume and good cost control in the quarter. 2024 full year all-time high EBITDA of MNOK 104 compared to MNOK 86 last year, a 21% increase. The net profit ended at MNOK 19.4 for the fourth quarter of 2024. Vistin...

Press releaseParis, 13 February 2025 Financial results at 31 December 2024 Strong 2024 results, 2025 Organic Cash Flow target raisedOrange is accelerating the implementation of its Lead the Future strategic plan 2024 targets fully achieved: EBITDAaL +2.7% year on year and Organic Cash Flow of 3.4 billion euros Orange confirms its 2025 targets and raises its Organic Cash Flow target to at least 3.6 billion eurosIn millions of euros   4Q 2024 changecomparablebasis changehistoricalbasis   12M 2024 changecomparablebasis changehistoricalbasisRevenues   10,426 0.5 % (0.1)%   40,260 1.2 % 1.5 %EBITDAaL   3,252 3.2 % 1.4 %   12,109 2.7 % 2.7 %Operating Income           5,116 14.8 % 8.1 %Consolidated net income           2,902   0.3 %o/w Consolidated net income of continuing operations           2,695   0.2 %o/w Consolidated...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline® (lanreotide) sales grew by 5.6%, while all other products, excluding Somatuline, achieved double-digit sales growth at 12.2%FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total salesContinued pipeline expansion in 2024, with significant regulatory approvals, addition of several preclinical therapies with global rights and innovative modalities, and a late-stage assetFour key regulatory and clinical milestones expected in 2025, including the Proof-of-Concept data readout for the Long-Acting Neurotoxin (LANT)Financial guidance2...